Skip to main content

Table 1 Patients classification according to their response to BRC

From: Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

Patient number

Serum PRL levels (μg/ml)

Tumor size(cm)

Higher BRC dose (mg/day)

Months with higher BRC dose

Classification

Before BRC

With BRC

Normal?

 

1

928

3.9

YES

2

5

6

Responsive

2

4843

15

YES

2.5

2.5

10

Responsive

3

122.3

3.18

YES

1.8

2.5

3

Responsive

4

899

7.6

YES

4.5

7.5

6

Responsive

5

3117

9.2

YES

2.5

7.5

3

Responsive

6

3830

15.5

YES

2

5

8

Responsive

7

975

165

NO

3.5

15

4

Resistant

8

>6000

268

NO

3

15

5

Resistant

9

182

83.2

NO

2

15

5

Resistant

10

>6000

68.2

NO

2.5

15

6

Resistant

11

2899

128.6

NO

5

15

24

Resistant

12

168

150

NO

0.8

15

6

Resistant